AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M
This article was originally published in The Pink Sheet Daily
Executive Summary
By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.
You may also be interested in...
Merck/AstraZeneca Stay Tied To Each Other For Another Two Years
Merck and AstraZeneca continue a 30-year partnership after coming to terms that could benefit both companies.
AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds
U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.
AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing
Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas